All in the family: Using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors

Journal of Cellular Biochemistry

Volumn 102, Issue 4, 2007, Pages 811-819

  Houshmandi, S Sean ^a   Gutmann, David H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8111 ^*  (United States)

Author keywords

Brain tumor signaling; Merlin; Neurofibromatosis 1; Neurofibromatosis 2; Neurofibromin; NF1; NF2; Schwannomin; TSC1 hamartin; TSC2 tuberin; Tuberous sclerosis complex

Indexed keywords

BRAIN TUMOR; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL MOTILITY; CELL MOTION; CELL PROLIFERATION; HUMAN; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; TUMOR GROWTH;

BRAIN NEOPLASMS; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; NERVOUS SYSTEM; NEUROFIBROMATOSES; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

EID: 35648959295     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21506     Document Type: Review

References (50)

1. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. 2002. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 22:5100-5113.
2. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH. 2003. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63:8573-8577.
3. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148.
4. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N Engl J Med 355:1345-1356.
5. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. 2007. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177:893-903.
6. Daginakatte GC, Gutmann DH. 2007. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16:1098-1112.
7. Dasgupta B, Dugan LL, Gutmann DH. 2003. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 23:8949-8954.
8. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. 2005. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 65:2755-2760.
9. European Chromosome 16 Tuberous Sclerosis Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315.
10. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. 1992. A clinical study of type 2 neurofibromatosis. Q J Med 84:603-618.
11. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. 2006. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498.
12. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
13. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF., et al. 2005. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304.
14. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G. 2003. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457-1466.
15. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G. 2000. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617-1630.
16. Gomez M, Sampson J, Whittemore VH. 1999. Tuberous sclerosis 3rd edition. New York: Oxford University Press.
17. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57.
18. Inoki K, Li Y, Xu T, Guan KL. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829-1834.
19. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumor predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7:353-361.
20. Jin H, Sperka T, Herrlich P, Morrison H. 2006. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442:576-579.
21. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102:8573-8578.
22. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M. 2002. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-1065.
23. Knudson AG, Jr. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
24. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. 1999. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59:1206-1211.
25. Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T, Hino O. 2001. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci USA 98:8762-8767.
26. Kwiatkowski DJ, Manning BD. 2005. Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14:251-258.
27. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. 2003. NF2 deficiency promotes tumori-genesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090-1100.
28. Listernick R, Louis DN, Packer RJ, Gutmann DH. 1997. Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143-149.
29. Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, Mitchell AL, Gutmann DH, Boguski M, Collins FS. 1991. cDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product. Genomics 11:931-940.
30. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. 1997. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 11:1253-1265.
31. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968-980.
32. Munchhof AM, Li F, White HA, Mead LE, Krier TR, Fenoglio A, Li X, Yuan J, Yang FC, Ingram DA. 2006. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum Mol Genet 15: 1858-1869.
33. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. 1994. Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450-461.
34. Potter CJ, Huang H, Xu T. 2001. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105:357-368.
35. Rong R, Surace EI, Haipek CA, Gutmann DH, Ye K. 2004. Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 23:8447-8454.
36. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B., et al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515-521.
37. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM. 2002. Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 11:3179-3189.
38. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1:63-72.
39. Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P, Gutmann DH. 1997. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505-2509.
40. Sun CX, Robb VA, Gutmann DH. 2002. Protein 4.1 tumor suppressors: Getting a FERM grip on growth regulation. J Cell Sci 115:3991-4000.
41. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. 2001. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345-355.
42. Tee AR, Anjum R, Blenis J. 2003. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 278:37288-37296.
43. Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y. 2002. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 5:95-96.
44. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K., et al. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800.
45. Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada K, Gutmann DH. 2002. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 52:285-296.
46. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J., et al. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808.
47. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA., et al. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192.
48. Wong M, Ess KC, Uhlmann EJ, Jansen LA, Li W, Crino PB, Mennerick S, Yamada KA, Gutmann DH. 2003. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol 54:251-256.
49. Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F. 1990. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63:835-841.
50. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. 2002. Neurofibromas in N F1:Schwann cell origin and role of tumor environment. Science 296:920-922.